Engage SuperAging.AI for cohort studies, real-world evidence work, data intelligence subscriptions, and advisory.

Cohort studies & sponsored research

We structure sponsored observational work, pragmatic extension studies, longitudinal safety characterization, adherence and behaviour arms, phenotype discovery pilots, biomarker-aligned feasibility packages, and late-phase adjunct RWE lanes when scientific and consent envelopes align.

Typical programme calendars run six to eighteen months contingent on phenotype complexity, ingestion depth, adjudication burdens, IRB modality, and intercurrent data-quality gates. Engagement economics are anchored on phenotype hypotheses, deterministic milestone delivery, residual risk partitioning, and whether narrative or conversational assets are invoked — indicative all-in engagements often land USD $250k–$3M, materially higher when bespoke ingestion, central lab choreography, adjudication councils, or third-party Endpoint Assessment Committees are stipulated.

Illustrative study families we support:

• Excessive daytime somnolence / sleep-architecture phenotype discrimination in septuagenarians.
• Cognitive trajectory stability vs decline flags conditioned on multimodal lifestyle signals.
• Sleep–cognition coupling hypotheses under perturbations (travel, seasonal light, cardiometabolic flare).
• Medication adherence choreography in insured 65+ populations with dispensing proxies where contractually permissible.
• Early functional-decline alerting models exploiting fused wearable + conversational sentiment gradients.

Data intelligence subscriptions

Annual licences deliver recurring, de-identified phenotype surfaces, multimodal longitudinal trajectories, and — where consented for specific research strata — curated Life Statement narrative motifs and conversational transcript excerpts aligned alongside biometric deltas. Intended for payer analytics benches, pharma epidemiology desks, AMC quant groups, and endowed chairs requiring continuous ingestion rather than one-off transactional extracts.

Pricing is quoted on inquiry, indexed to population breadth, phenotype depth, refresh cadence, linkage permissions, egress modality, subcontract depth, indemnity envelopes, minimum term, and audit rights. Outputs route through contractual DUA instruments, sanctioned API layers, or compartmentalised research workbench tenancy.

Advisory & methodology

We consult on phenotype dictionary design, protocol feasibility against our engaged population, methodological licensing of the Life Statement scaffolding, integration of multimodal ingestion across the canonical ten-domain coaching canvas, and BrainHQ-aligned cognitive pacing where studies require calibrated micro-check density.

Academic partnership subcontracts can map to NIH R-series, UC2/UG3 mechanisms, pragmatic trial coordinating centers, or foundation-specific grant vehicles when indirect cost and IP firewalls comply with sponsoring institution rulesets.

Compliance & governance

Institutional sponsors and AMC IRBs expect operational literalism — summarized here at a high level; definitive obligations are contract and protocol specific.

• Privacy & regulatory alignment: HIPAA Business Associate relationships where required; consent stratification surfaced per study arm; segregation of PHI from de-identified research feeds unless additional explicit authorization corridors are opened under IRB-reviewed instruments.
• IRB pathway: reliance agreements, reciprocity letters, centralized vs local review — we interoperate with sponsor IRB of record and maintain traceable versioning of questionnaires, instruments, and data-flow diagrams underpinning deterministic audit.
• Consent architecture: tiered granularity for biometric-only vs narrative vs transcript-derived secondary analytics; revocation and cooling-off behaviours respected at the ingestion edge.
• Data use agreements & publication: pre-negotiated publication rights, attribution, statistical review timelines, and residual re-identification risk minimization methodologies (including expert determination where applicable).
• Safeguards by default: no discretionary sharing of PHI or sensitive narrative beyond envelopes approved in active instruments; researcher-facing surfaces default to minimized cohorts unless protocol calls for narrower cohort keys with statistical disclosure control review.